Cevimeline hydrochloride | CAS#107220-28-0 | cholinergic agonist

MedKoo Cat#: 591283 | Name: Cevimeline HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cevimeline HCl is a cholinergic agonist that binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands, and increase tone of the smooth muscle in the GI and urinary tracts.

Chemical Structure

Cevimeline HCl

CAS#107220-28-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 591283

Name: Cevimeline HCl

CAS#: 107220-28-0 (HCl)

Chemical Formula: C10H18ClOS

Exact Mass: 0.0000

Molecular Weight: 235.77

Elemental Analysis: C, 50.94; H, 7.70; Cl, 15.04; N, 5.94; O, 6.79; S, 13.60

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
25mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

107233-08-9 (free base) 107220-28-0 (HCl)

Synonym

Cevimeline hydrochloride; Evoxac; Cevimeline HCl; AF-102B; AF 102B; AF102B; FKS 508; FKS-508; FKS508; SNI 2011; SNI-2011; SNI2011; SNK 508; SNK-508; SNK508; Cevimeline;

IUPAC/Chemical Name

(2R,2'R)-2'-methyl-4-azaspiro[bicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride

InChi Key

SURWTGAXEIEOGY-GHXDPTCOSA-N

InChi Code

InChI=1S/C10H17NOS.ClH/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;/h8-9H,2-7H2,1H3;1H/t8-,10-;/m1./s1

SMILES Code

C[C@@H](SC1)O[C@@]21CN3CCC2CC3.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Cevimeline hydrochloride (AF102B hydrochloride) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist.

In vitro activity:

In the present study, we examined immunoreactivities for mAChR subtypes in SSN neurons retrogradely labeled with a fluorescent tracer in neonatal rats. Additionally, we examined the effects of cevimeline in labeled SSN neurons of brainstem slices using a whole-cell patch-clamp technique. Mainly M1 and M3 receptors were detected by immunohistochemical staining, with low-level detection of M4 and M5 receptors and absence of M2 receptors. Most (110 of 129) SSN neurons exhibited excitatory responses to application of cevimeline. In responding neurons, voltage-clamp recordings showed that 84% (101/120) of the neurons exhibited inward currents. In the neurons displaying inward currents, the effects of the mAChR antagonists were examined. A mixture of M1 and M3 receptor antagonists most effectively reduced the peak amplitude of inward currents, suggesting that the excitatory effects of cevimeline on SSN neurons were mainly mediated by M1 and M3 receptors. Current-clamp recordings showed that application of cevimeline induced membrane depolarization (9/9 neurons). These results suggest that most SSN neurons are excited by cevimeline via M1 and M3 muscarinic receptors. Reference: Auton Neurosci. 2017 Sep;206:1-7. https://linkinghub.elsevier.com/retrieve/pii/S1566-0702(17)30050-4

In vivo activity:

This study investigated whether the co-treatment of cevimeline (a M3 receptor agonist) could prevent the metabolic side-effects associated with olanzapine medication. Female Sprague Dawley rats were treated orally with olanzapine (2 mg/kg, t.i.d.) and/or cevimeline at 3 dosages (3, 6, 9 mg/kg, t.i.d.), or vehicle for two weeks. Weight gain and food/water intake were measured throughout the drug treatment period. Intraperitoneal glucose tolerance tests and open field tests were conducted. Olanzapine-treated rats demonstrated significantly elevated body weight gain, food intake, feeding efficiency, total white fat mass, liver mass, and plasma triglyceride levels, which could be partly reversed by the co-treatment with cevimeline in a dosage-dependent manner. In general, the body weight gain can only be reversed by the co-treatment of 9 mg/kg cevimeline. The cevimeline co-treatment decreased plasma triglyceride and glucose levels compared with olanzapine only treatment. The results suggested a dosage-dependent effect of cevimeline in ameliorating olanzapine-induced weight gain and metabolic side-effects, which supports further clinical trials using cevimeline to control weight gain and metabolic side-effects caused by antipsychotic medications. Reference: Pharmacol Biochem Behav. 2020 Apr;191:172878. https://linkinghub.elsevier.com/retrieve/pii/S0091-3057(19)30640-9

	Solvent	mg/mL	mM
Solubility
	Water	50.0	212.07

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 235.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1. Mitoh Y, Ueda H, Ichikawa H, Fujita M, Kobashi M, Matsuo R. Effects of cevimeline on excitability of parasympathetic preganglionic neurons in the superior salivatory nucleus of rats. Auton Neurosci. 2017 Sep;206:1-7. doi: 10.1016/j.autneu.2017.05.010. Epub 2017 May 30. PMID: 28600120.

In vivo protocol:

1. Lian J, Deng C. The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats. Pharmacol Biochem Behav. 2020 Apr;191:172878. doi: 10.1016/j.pbb.2020.172878. Epub 2020 Feb 26. PMID: 32112786. 2. Nishimura H, Yakeishi A, Saga T, Yamaki K. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice. Kurume Med J. 2009;56(3-4):39-47. doi: 10.2739/kurumemedj.56.39. PMID: 20505281.

1: Malallah OS, Garcia CMA, Proctor GB, Forbes B, Royall PG. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth). Int J Pharm. 2018 Apr 25;541(1-2):157-166. doi: 10.1016/j.ijpharm.2018.02.004. Epub 2018 Feb 6. Review. PubMed PMID: 29425763. 2: Togashi H, Matsumoto M, Yoshioka M, Saito Y, Saito H. Effects of a novel cholinergic M1 agonist, AF102B, on ambulation and water drinking behavior in rats. Hokkaido Igaku Zasshi. 1991 Jan;66(1):59-66. PubMed PMID: 2004736.